Lotus Pharmaceuticals and Teraju Pharma have entered a strategic partnership to market Lotus’s products in a range of therapeutic areas in Malaysia.

Teraju Pharma will be responsible for marketing and promoting the products using its relationships and infrastructure.

The company is a specialised pharmaceutical wholesaler and holds a licence, issued by the country’s ministry of health, to import non-registered pharmaceutical products, orphan drugs and other life-saving medicines.

It sources a wide range of branded or generic equivalent drugs from across the globe to meet the needs of the local market.

Lotus Pharmaceuticals CEO Petar Vazharov stated: “We are delighted at our new collaboration with Teraju.

“This partnership will enable us to establish a substantial presence in Malaysia, particularly in the oncology sector, which leverages high-quality manufacturing and a rich pipeline of products.”

How well do you really know your competitors?

Access the most comprehensive Company Profiles on the market, powered by GlobalData. Save hours of research. Gain competitive edge.

Company Profile – free sample

Thank you!

Your download email will arrive shortly

Not ready to buy yet? Download a free sample

We are confident about the unique quality of our Company Profiles. However, we want you to make the most beneficial decision for your business, so we offer a free sample that you can download by submitting the below form

By GlobalData
Visit our Privacy Policy for more information about our services, how we may use, process and share your personal data, including information of your rights in respect of your personal data and how you can unsubscribe from future marketing communications. Our services are intended for corporate subscribers and you warrant that the email address submitted is your corporate email address.

The company confirmed that the alliance is in line with its strategic plan to expand in Southeast Asia.

The collaboration will launch a portfolio of products in the therapeutic categories of ophthalmology, cardio-metabolic and oncology, commencing in the fourth quarter of 2023.

Lotus Pharmaceuticals, Alvogen and NRx Pharmaceuticals recently signed a global collaboration agreement for the development and commercialisation of NRX-101 to treat suicidal treatment-resistant bipolar depression (S-TRBD). 

The company will buy worldwide rights for the therapy and handle its commercialisation activities in markets outside the US.